Interleukin-17 inhibition in psoriatic arthritis

The Lancet

Volumn 386, Issue 9999, 2015, Pages 1114-1116

  Helliwell, Philip ^a   Coates, Laura ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 17 ANTIBODY; SECUKINUMAB; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

DISEASE ACTIVITY; DRUG SAFETY; HUMAN; NOTE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PSORIATIC ARTHRITIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SKIN MANIFESTATION; ARTHRITIS, PSORIATIC; FEMALE; MALE;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; FEMALE; HUMANS; MALE;

EID: 84942196033     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(15)61170-9     Document Type: Note

References (12)

1. JM Moll, V Wright Psoriatic arthritis Semin Arthritis Rheum 3 1973 55 78
2. ME Roberts, V Wright, AG Hill, AC Mehra Psoriatic arthritis. Follow-up study Ann Rheum Dis 35 1976 206 212
3. KB Sokoll, PS Helliwell Comparison of disability and quality of life in rheumatoid and psoriatic arthritis J Rheumatol 28 2001 1842 1846
4. C Ritchlin, A Kavanaugh, DD Gladman et al. Treatment recommendations for psoriatic arthritis Ann Rheum Dis 68 2009 1387 1394
5. AF Kavanaugh, CT Ritchlin GRAPPA Treatment Guideline Committee Systematic review of treatments for psoriatic arthritis: an evidence based approach and basis for treatment guidelines J Rheumatol 33 2006 1417 1421
6. AA Saad, DM Ashcroft, KD Watson, KL Hyrich, PR Noyce, DP Symmons the British Society for Rheumatology Biologics Register Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register Arthritis Res Ther 11 2009 R52
7. RG Langley, BE Elewski, M Lebwohl et al. Secukinumab in plaque psoriasis - results of two phase 3 trials N Engl J Med 371 2014 326 338
8. CE Griffiths, K Reich, M Lebwohl for the UNCOVER-2 UNCOVER-3 investigators Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials Lancet 2015 published online June 10. http://dx.doi.org/10.1016/S0140-6736(15)60125-8
9. IB McInnes, PJ Mease, B Kirkham on behalf of the FUTURE 2 Study Group Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial Lancet 2015 published online June 29. http://dx.doi.org/10.1016/S0140-6736(15)61134-5
10. PJ Mease, IB McInnes, B Kirkham et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, improves active psoriatic arthritis and inhibits radiographic progression: efficacy and safety data from a phase 3 randomized, multicenter, double-blind, placebo-controlled study Arthritis Rheum 66 suppl 2014 S423 (abstr 923).
11. C Ritchlin, P Rahman, A Kavanaugh et al. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial Ann Rheum Dis 73 2014 990 999
12. LC Coates, AR Moverley, L McParland et al. Results of a randomised controlled trial comparing tight control of early psoriatic arthritis (TICOPA) with standard care: tight control improves outcome Arthritis Rheum 65 2013 S346